GenomOncology, a precision medicine software company, has announced a strategic partnership with Chronetyx Laboratories aimed at significantly reducing turnaround times for next-generation sequencing (NGS) testing results in cancer care. The collaboration, announced on March 31, 2025, integrates GenomOncology's Pathology Workbench with Chronetyx Laboratories' NGS and information systems to streamline the delivery of critical genomic insights to healthcare providers.
The partnership specifically supports Chronetyx's FDA-cleared and CE-IVD-Marked Cyx Solid Tumor 505 test, enabling physicians to receive comprehensive genomic profiling results faster and make more timely treatment decisions for cancer patients.
Addressing Critical Time Gaps in Precision Medicine
A significant challenge in precision oncology has been the delay between tumor sample collection and the delivery of actionable genomic results. This partnership directly addresses this issue by implementing GenomOncology's Pathology Workbench as the tertiary analysis and clinical genomic reporting platform for Chronetyx's testing services.
"In cancer care, time to treatment matters. Our partnership with GenomOncology transforms how quickly we can deliver crucial genomic insights to physicians," said Tim Hodge, president at Chronetyx Laboratories. "By automating our workflow and integrating directly with our laboratory systems, we're not just saving time – we're helping doctors make faster, more informed decisions about their patients' treatments."
The integration eliminates manual processes and automates complex genomic interpretations, substantially reducing the time required to deliver results to treating physicians.
Enhanced Testing Platform Benefits
The newly integrated platform delivers several immediate improvements to cancer care delivery:
- Automated workflows that streamline data entry and analysis
- Enhanced speed and efficiency in results delivery
- Automatic identification and prioritization of clinically significant genomic findings
- Standardized, comprehensive reports that integrate seamlessly with electronic health records
Garreth Hippe, Chief Commercial Officer at GenomOncology, emphasized the importance of this advancement: "Time is a crucial factor in cancer treatment, and our partnership with Chronetyx Laboratories directly addresses this challenge. By streamlining the testing workflow and automating complex genomic analysis, we're helping ensure that patients receive the right treatment at the right time, based on the genetic profile of the patient's tumor."
Facilitating Multidisciplinary Collaboration
Beyond improving testing efficiency, the platform supports real-time collaboration between pathologists, oncologists, and other healthcare providers. This enhanced communication capability enables faster consultation on complex cases and reduces delays in treatment initiation.
The system ensures that critical genetic findings are quickly translated into actionable treatment decisions, potentially improving outcomes for cancer patients who benefit from precision medicine approaches.
Technological Integration Details
The partnership leverages GenomOncology's expertise in bioinformatics and clinical decision support with Chronetyx Laboratories' advanced diagnostic capabilities. The integration specifically:
- Connects GenomOncology's Pathology Workbench directly with Chronetyx's laboratory information systems
- Automates the interpretation of complex genomic data from the Cyx Solid Tumor 505 test
- Provides standardized reporting that highlights clinically relevant mutations and potential therapeutic options
- Enables seamless integration with existing electronic health record systems
This technological integration represents a significant advancement in how genomic data is processed and delivered in clinical oncology settings, potentially setting a new standard for precision medicine implementation.
Implications for Cancer Care
The partnership between GenomOncology and Chronetyx Laboratories demonstrates how technological innovation can address practical challenges in delivering precision medicine. By reducing the time between testing and treatment decisions, this collaboration may help improve patient outcomes through more timely intervention with targeted therapies.
As genomic testing becomes increasingly central to cancer treatment planning, solutions that streamline the delivery of results and support clinical decision-making will play a crucial role in advancing personalized medicine and improving the standard of care for cancer patients.
